Rhonda Farnum Sells 31,067 Shares of Theravance Biopharma (NASDAQ:TBPH) Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $18.75, for a total value of $582,506.25. Following the transaction, the senior vice president directly owned 277,695 shares of the company’s stock, valued at $5,206,781.25. The trade was a 10.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Theravance Biopharma Stock Down 0.8%

TBPH traded down $0.15 during trading on Friday, reaching $18.55. The company’s stock had a trading volume of 245,160 shares, compared to its average volume of 326,145. The firm has a fifty day simple moving average of $16.00 and a two-hundred day simple moving average of $13.30. The company has a market cap of $939.93 million, a price-to-earnings ratio of 32.54 and a beta of 0.14. Theravance Biopharma, Inc. has a 1 year low of $7.90 and a 1 year high of $20.33.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.10. The business had revenue of $19.99 million during the quarter, compared to analysts’ expectations of $19.89 million. Theravance Biopharma had a net margin of 36.53% and a return on equity of 12.20%. As a group, equities analysts forecast that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Theravance Biopharma

Several hedge funds have recently added to or reduced their stakes in TBPH. Quarry LP purchased a new stake in Theravance Biopharma in the third quarter valued at $26,000. Caitong International Asset Management Co. Ltd grew its position in Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 1,411 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 781 shares in the last quarter. CIBC Private Wealth Group LLC lifted its holdings in shares of Theravance Biopharma by 20,269.6% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 4,662 shares during the period. Finally, SG Americas Securities LLC acquired a new position in shares of Theravance Biopharma during the 3rd quarter worth $101,000. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on TBPH. Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a research report on Wednesday, October 8th. Wall Street Zen upgraded Theravance Biopharma from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 23rd. BTIG Research boosted their price target on shares of Theravance Biopharma from $25.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, November 26th. Oppenheimer assumed coverage on shares of Theravance Biopharma in a research report on Wednesday. They set an “outperform” rating and a $27.00 price target on the stock. Finally, Zacks Research cut shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, September 15th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $27.80.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.